Biofrontera Inc. (NasdaqCM: BFRI)
Health Care · Pharmaceuticals · US
$1.54
+4.05% today · +60.5% 1Y
Biofrontera Inc. (NasdaqCM: BFRI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $21.98M and employs 89 people.
Over the last twelve months the share price has gained 60.5%, trading between 0.55 and 1.52.
Tweenvest scores Biofrontera Inc. across four factors: quality 27/100, value 60/100, growth 74/100. Its strongest factor is growth.
BFRI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $21.98M
- Revenue (TTM)
- $46.17M
- P/E
- —
- EPS
- -0.54
- Dividend yield
- —
- Beta (5Y)
- 0.80
- 52-week high
- $1.52
- 52-week low
- $0.55
- Avg volume (3M)
- —
- Shares outstanding
- 14.85M
- Employees
- 89
- Next earnings
- —
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
- ISIN
- US09077D2099
- Founded
- 2015
- Listed since
- Oct 29, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,190.85 | -3.47% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.06 | -0.76% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.94 | -1.60% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.25 | -1.14% |
Figures last refreshed Aug 18, 2026.